Researchers from the QIMR Berghofer Medical Research Institute in Queensland, Australia and Emory University have shown that a potential new targeted therapy for childhood brain cancer was effective in infiltrating and killing tumor cells in mouse models. Read More
Mouse models for hemophilia A are commonly generated by factor VIII (FVIII) knockout, however, these mice rapidly develop anti-FVIII antibodies during repetitive FVIII administration. To overcome this preclinical research challenge, investigators from Octapharma AG and affiliated organizations developed a new model unable to produce antibodies but otherwise not immunosuppressed. Read More
Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, from Genome & Co. Ltd. Targeting CNTN4 is a new approach that blocks the CNTN4-APP checkpoint interaction on T cells, promoting tumor cell killing, with potential use in cancers that respond poorly to conventional checkpoint inhibitors. Read More
Death receptor 3 (DR3) is the only signaling receptor for TNF superfamily ligand TL1A, the dysregulation of which has been implicated in multiple inflammatory diseases such as inflammatory bowel disease (IBD). Blockade of TL1A has been shown to induce significant clinical responses in IBD. Read More
Researchers from the Centre for Addiction and Mental Health (CAMH) and affiliated organizations presented preclinical data for the α5-GABA-A receptor (α5-GABAAR) positive allosteric modulator GL-II-73 (DPX-101), which is being developed by Damona Pharmaceuticals Inc. for the treatment of Alzheimer’s disease and other cognitive and neurological disorders. Read More
With the first company in the world announcing more than $1 billion in annual revenue from pulsed field ablation on Feb. 5, Clarivate plc and BioWorld MedTech’s latest report provides well-timed insight into the stunning growth and bright future of this new medical technology for the treatment of atrial fibrillation. Read More
Several Gluetacs Therapeutics (Shanghai) Co. Ltd. patents describe molecular glue degraders reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders. Read More
Ulcerative colitis is a chronic, immune-mediated disorder of the colon and rectum characterized by mucosal inflammation that damages the bowel wall surface. Current therapeutic options include 5-aminosalicylates, corticosteroids or anti-TNF agents, but there is a need for new strategies to obtain higher remission rates and less systemic immunosuppression. Read More
Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic diseases, cardiovascular, inflammatory and immunological disorders. Read More
Leishmaniasis is a life-threatening parasitic infection and one of the most concerning neglected vector-borne tropical diseases worldwide. Current leishmaniasis chemotherapeuticals are poorly effective and cause significant adverse effects. Metal-containing drugs have been little explored as antibacterial and antiparasitic agents, although some have shown promise against Leishmania. Read More
Asieris Pharmaceuticals Co. Ltd. has synthesized new protein arginine N-methyltransferase 5 (PRMT5) inhibitors described as potentially useful for the treatment of bladder cancer. Read More
Microglia play a crucial role in neuroinflammation after ischemic brain injury. Previous data have shown that leukocyte immunoglobulin-like receptor B4 (LILRB4) was upregulated in mice after middle cerebral artery occlusion (MCAO), but the role it plays here is not well understood. The role LILRB4 plays in ischemic brain injury was thus investigated. LILRB4 expression was measured in mice at different time points after MCAO. Read More
Previous research has shown that cell division cycle associated 4 (CDCA4) is overexpressed in multiple tumors and is involved in tumor progression. Researchers from Yangtze University and affiliated organizations investigated the role of CDCA4 in bladder cancer. Read More
An Inventisbio Co. Ltd. and Inventisbio LLC patent discloses new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome). Read More
